| Year |
Citation |
Score |
| 2020 |
Maharaj K, Powers JJ, Mediavilla-Varela M, Achille A, Gamal W, Quayle S, Jones SS, Sahakian E, Pinilla-Ibarz J. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model. Frontiers in Immunology. 11: 590072. PMID 33329575 DOI: 10.3389/fimmu.2020.590072 |
0.627 |
|
| 2020 |
Maharaj K, Powers JJ, Achille A, Mediavilla-Varela M, Gamal W, Burger KL, Fonseca R, Jiang K, Miskin HP, Maryanski D, Monastyrskyi A, Duckett DR, Roush WR, Cleveland JL, Sahakian E, et al. The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Advances. 4: 3072-3084. PMID 32634240 DOI: 10.1182/Bloodadvances.2020001800 |
0.614 |
|
| 2019 |
Mediavilla-Varela M, Agrawal V, Page MM, Kreahling J, Altiok S. Abstract 34: A high-content imaging platform for quantitative assessment of immunogenic tumor cell killing and T-cell proliferation in 3D tumoroids of fresh patient tumor samples Cancer Research. 79: 34-34. DOI: 10.1158/1538-7445.Sabcs18-34 |
0.383 |
|
| 2019 |
Agrawal V, Mediavilla-Varela M, Page MM, Kreahling J, Altiok S. Abstract 42: The importance of intact tumor immune microenvironment in unpropagated 3D fresh patient tumoroids in immuno-oncology drug testing for immunogenic tumor cell death and T-cell activation Cancer Research. 79: 42-42. DOI: 10.1158/1538-7445.Am2019-42 |
0.374 |
|
| 2018 |
Gray JE, Chiappori A, Williams CC, Tanvetyanon T, Haura EB, Creelan BC, Kim J, Boyle TA, Pinder-Schenck M, Khalil F, Altiok S, Devane R, Noyes D, Mediavilla-Varela M, Smilee R, et al. A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma. Cancer Immunology, Immunotherapy : Cii. PMID 30209589 DOI: 10.1007/S00262-018-2236-7 |
0.332 |
|
| 2018 |
Mediavilla-Varela M, Page MM, Kreahling J, Altiok S. Abstract 1020: Characterization of the immune landscape and analysis of tumor response after anti-PD-1 blockade in a 3Dex vivosystem of non-small lung cancer Tumor Biology. DOI: 10.1158/1538-7445.Am2018-1020 |
0.301 |
|
| 2017 |
Mediavilla-Varela M, Castro J, Chiappori A, Noyes D, Hernandez DC, Stagg J, Antonia SJ. A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment. Neoplasia (New York, N.Y.). 19: 530-536. PMID 28582704 DOI: 10.1016/J.Neo.2017.02.004 |
0.321 |
|
| 2017 |
Mediavilla-Varela M, Page MM, Kreahling J, Freimark BD, Shan J, Kallinteris NL, Antonia SJ, Altiok S. Effect of bavituximab in combination with nivolumab on tumor immune response in a 3D ex vivo system of lung cancer patients. Journal of Clinical Oncology. 35: e23091-e23091. DOI: 10.1200/Jco.2017.35.15_Suppl.E23091 |
0.378 |
|
| 2017 |
Mediavilla-Varela M, Page MM, Kreahling J, Antonia SJ, Altiok S. Anti-PD1 treatment to induce M1 polarization of tumor infiltrating macrophages in a 3D ex vivo system of lung cancer patients. Journal of Clinical Oncology. 35: e23090-e23090. DOI: 10.1200/Jco.2017.35.15_Suppl.E23090 |
0.335 |
|
| 2016 |
Mediavilla-Varela M, Boateng K, Noyes D, Antonia SJ. The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts. Bmc Cancer. 16: 176. PMID 26935219 DOI: 10.1186/S12885-016-2162-Z |
0.352 |
|
| 2016 |
Basu A, Cajigas-Du Ross CK, Rios-Colon L, Mediavilla-Varela M, Daniels-Wells TR, Leoh LS, Rojas H, Banerjee H, Martinez SR, Acevedo-Martinez S, Casiano CA. LEDGF/p75 Overexpression Attenuates Oxidative Stress-Induced Necrosis and Upregulates the Oxidoreductase ERP57/PDIA3/GRP58 in Prostate Cancer. Plos One. 11: e0146549. PMID 26771192 DOI: 10.1371/Journal.Pone.0146549 |
0.773 |
|
| 2014 |
Gordian E, Li J, Pevzner Y, Mediavilla-Varela M, Luddy K, Ohaegbulam K, Daniel KG, Haura EB, Muñoz-Antonia T. Transforming growth factor β signaling overcomes dasatinib resistance in lung cancer. Plos One. 9: e114131. PMID 25501935 DOI: 10.1371/Journal.Pone.0114131 |
0.396 |
|
| 2014 |
Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W, Diao L, Wang J, Roybal JD, Patel M, Ungewiss C, ... ... Mediavilla-Varela M, et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nature Communications. 5: 5241. PMID 25348003 DOI: 10.1038/Ncomms6241 |
0.329 |
|
| 2014 |
Pacheco FJ, Almaguel FG, Evans W, Rios-Colon L, Filippov V, Leoh LS, Rook-Arena E, Mediavilla-Varela M, De Leon M, Casiano CA. Docosahexanoic acid antagonizes TNF-α-induced necroptosis by attenuating oxidative stress, ceramide production, lysosomal dysfunction, and autophagic features. Inflammation Research : Official Journal of the European Histamine Research Society ... [Et Al.]. 63: 859-71. PMID 25095742 DOI: 10.1007/S00011-014-0760-2 |
0.711 |
|
| 2014 |
Mediavilla-Varela M, Noyes D, Boateng K, Antonia S. Abstract 1704: Combination of Pirfenidone and Cisplatin as a potential therapeutic strategy in NSCLC Cancer Research. 74: 1704-1704. DOI: 10.1158/1538-7445.Am2014-1704 |
0.397 |
|
| 2013 |
Mediavilla-Varela M, Luddy K, Noyes D, Khalil FK, Neuger AM, Soliman H, Antonia SJ. Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biology & Therapy. 14: 860-8. PMID 23917542 DOI: 10.4161/Cbt.25643 |
0.395 |
|
| 2013 |
Mediavilla-Varela M, Luddy K, Noyes D, Boateng K, Antonia S. Abstract 4948: Pirfenidone as a potential therapeutic treatment for CAFs and cancer cells in NSCLC. Cancer Research. 73: 4948-4948. DOI: 10.1158/1538-7445.Am2013-4948 |
0.438 |
|
| 2013 |
Basu A, Cajigas C, Medina B, Rojas H, Banerjee H, Mediavilla-Varela M, Leoh L, Casiano C. Abstract 3117: Overexpression of the stress transcription co-activator LEDGF/p75 contributes to the upregulation of the stress protective genes HSP27, ERp57 and CYGB in prostate cancer. Cancer Research. 73: 3117-3117. DOI: 10.1158/1538-7445.Am2013-3117 |
0.818 |
|
| 2011 |
Leoh LS, Mediavilla-Varela M, Basu A, Daniels TR, Martinez S, Pacheco FJ, Padilla A, Asuelime G, Rios-Colon L, Leon MD, Casiano CA. Abstract 2083: The stress oncoprotein LEDGF/p75 attenuates oxidative stress-induced necrosis but not apoptosis in prostate cancer cells Cancer Research. 71: 2083-2083. DOI: 10.1158/1538-7445.Am2011-2083 |
0.743 |
|
| 2010 |
Soliman H, Mediavilla-Varela M, Antonia S. Indoleamine 2,3-dioxygenase: is it an immune suppressor? Cancer Journal (Sudbury, Mass.). 16: 354-9. PMID 20693847 DOI: 10.1097/Ppo.0B013E3181Eb3343 |
0.344 |
|
| 2010 |
Basu A, Mediavilla-Varela M, Martinez S, Rojas H, Banergee H, Roy S, Lilly MB, Leon MD, Casiano CA. Abstract 2715: Peroxiredoxin 3: A potential biological determinant of prostate cancer health disparities Cancer Research. 70: 2715-2715. DOI: 10.1158/1538-7445.Am10-2715 |
0.799 |
|
| 2010 |
Basu A, Banerjee H, Rojas H, Martinez S, Mediavilla-Varela M, Sourav R, Jia Z, Mercola D, Lilly MB, Leon MD, Casiano CA. Abstract A108: Differential expression of peroxiredoxins in prostate cancer: Ethnic differences in the association of PRDX3 expression with clinical outcomes Cancer Epidemiology, Biomarkers & Prevention. 19. DOI: 10.1158/1055-9965.Disp-10-A108 |
0.801 |
|
| 2009 |
Mediavilla-Varela M, Pacheco FJ, Almaguel F, Perez J, Sahakian E, Daniels TR, Leoh LS, Padilla A, Wall NR, Lilly MB, De Leon M, Casiano CA. Docetaxel-induced prostate cancer cell death involves concomitant activation of caspase and lysosomal pathways and is attenuated by LEDGF/p75. Molecular Cancer. 8: 68. PMID 19715609 DOI: 10.1186/1476-4598-8-68 |
0.758 |
|
| 2008 |
Brown-Bryan TA, Leoh LS, Ganapathy V, Pacheco FJ, Mediavilla-Varela M, Filippova M, Linkhart TA, Gijsbers R, Debyser Z, Casiano CA. Alternative splicing and caspase-mediated cleavage generate antagonistic variants of the stress oncoprotein LEDGF/p75. Molecular Cancer Research : McR. 6: 1293-307. PMID 18708362 DOI: 10.1158/1541-7786.Mcr-08-0125 |
0.739 |
|
| 2006 |
Casiano CA, Mediavilla-Varela M, Tan EM. Tumor-associated antigen arrays for the serological diagnosis of cancer. Molecular & Cellular Proteomics : McP. 5: 1745-59. PMID 16733262 DOI: 10.1074/Mcp.R600010-Mcp200 |
0.727 |
|
| Show low-probability matches. |